HC Wainwright Issues Positive Forecast for Greenwich LifeSciences (NASDAQ:GLSI) Stock Price

Greenwich LifeSciences (NASDAQ:GLSI) had its price target upped by research analysts at HC Wainwright from $50.00 to $69.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 377.15% from the stock’s previous close.

Several other equities analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research note on Saturday, June 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $57.00.

Greenwich LifeSciences Price Performance

GLSI stock traded up $0.39 during mid-day trading on Tuesday, reaching $14.46. The company had a trading volume of 173,132 shares, compared to its average volume of 248,992. Greenwich LifeSciences has a 52 week low of $7.78 and a 52 week high of $34.10. The company has a market capitalization of $212.29 million, a price-to-earnings ratio of -9.21 and a beta of 1.40. The stock has a 50 day simple moving average of $23.13 and a two-hundred day simple moving average of $24.60.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in GLSI. Bank of America Corp DE increased its holdings in shares of Greenwich LifeSciences by 22.3% during the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after acquiring an additional 1,322 shares during the last quarter. Rhumbline Advisers boosted its position in Greenwich LifeSciences by 48.7% during the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after purchasing an additional 3,168 shares during the period. Wells Fargo & Company MN boosted its position in Greenwich LifeSciences by 109.6% during the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock worth $165,000 after purchasing an additional 4,102 shares during the period. Strs Ohio acquired a new position in shares of Greenwich LifeSciences in the first quarter valued at $177,000. Finally, Jane Street Group LLC acquired a new position in shares of Greenwich LifeSciences in the fourth quarter valued at $203,000. 4.16% of the stock is currently owned by institutional investors.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.